Our latest report shows that the advent of new potential blockbusters in Europe is expected to position the European pharma industry with increased growth through to 2022 of 3.2% CAGR (2015-2022).
As the pharmaceutical pipeline continues to meet the demand for improved outcomes, question marks on the sustainability of the system as we know it continue to rise.
A unique solution from EvaluatePharma for European market sizing, R&D horizon scanning and price comparison utilising real world government and company reported sales data with country level, consensus based product forecasts to 2022.
EvaluatePharma delivers exclusive consensus sales forecasts and trusted commercial insight into biotech and pharmaceutical performance.
Request more information when you download the report.
